“The differences and similarities between axial disease in psoriatic arthritis vs axial spondyloarthritis is just at the cusp of discovery” Nigil Haroon at session 6S403 @RheumNow #ACR21

My exclusive interview w/the GRA Powerhouse! What are they studying next? 👉impact of COVID policies on Rheum pts 👉pt's perception w/COVID vaccines 👉COVID risk calculator 👉long haulers w/ rheum dz 👉breakthrough infections @rheumnow https://t.co/dVLayNchHT @rheum_covid https://t.co/B1KIjxYt15

• COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao - Y…

In this video, @rheumnow faculty recapped pre-ACR events, opening day lecture with @DrDavidKarp @DoctorYasmin year in review. #ACR21 @uptoTate @RHEUMarampa https://t.co/CO1uIyj1Z0 via @YouTube

• ACR21 Opening Day Recap: Drs. Cush, Dao, Tate and Reyes - YouTube

Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN

Prolonging the Controversy of Hydroxychloroquine Dr. Kathryn Dao (@KDAO2011 ) shares several abstracts from #ACR21 that addressed the topic of HCQ and cardiovascular safety. https://t.co/J6sVzYJkUZ https://t.co/dBZmtwQ927

• https://bit.ly/3wyEJTb

My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in patients with #SpA, with a focus on abstracts 0380 and 0381 by @ElenaNikiUK #axspa #spondyloarthritis #arthritis #qualityoflife Watch it here👇🏼 https://t.co/MEQ4wkFxrx

• Sick Leave and Work Disability in Patients with AxSpA: Dr. Mrinalini Dey | Rheu…

#ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, clinical features (fever pattern, rash and MSK symptoms) distinguished inflammation vs infection but not CRP, ferritin and procalcitonin @RheumNow https://t.co/s61WGBVK73 https://t.co/qhN95GdwgJ

• Role of Clinical and Laboratory Parameters in Differentiating Infection from Di…

A key reason I'm looking forward to in-person conferences again, is so I don't have to perform the mental gymnastics and stress of ensuring I make all the sessions and meetings on time! 😂 ⏰UK colleagues- time difference for #ACR21 will be +5️hours from tomorrow! @RheumNow https://t.co/wl7ij3vyOU

• American College of Rheumatology on Twitter: "#ACR21 Attendees – The Easte…

Top Influencers of #acr21: @ACRheum @rheum_cat @RheumNow @CreakyJoints @DoctorYasmin @KDAO2011 More 📊 https://t.co/vyMAwjKbqC

• #acr21 - ACR Convergence 2021 - Social Media Analytics and Transcripts

There is a strong association with pre-ICI autoantibody positivity and any-type irAE development as well as high specificity of RF and CCP for ICI-arthritis. Prospective evaluation of RF/CCP pre-treatment may be useful @RheumNow #ACR21 Abst#0440 https://t.co/P7L7pL1iuV

• Association Between Rheumatic Autoantibody Positivity and Immune-related Advers…

Excellent debate in #Lupus nephritis 6S214 with Wofsy, Isenberg & Costenbader. Q’s. What to do about Class V renal, many class III, IV LNdon’t go into sustained remission, cases of new onset LN in pts with #Belimumab ?more/less than expected, which drug to use @RheumNow #ACR21 https://t.co/tWbw79dE7d

Torgutalp et al. ⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-axSpA (symptom duration ≤10 y) from German Cohort ⭐️Assessed TNFI use over 2 years and has shown🔽 in radiographic sacroiliitis progression. Abst#0451 #ACR21 @RheumNow #ACRBest https://t.co/xP0wMLSyGw

RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers? ⬆️IL-22 in AxSpA vs. controls ⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP Abs#385 #ACR21 @RheumNow https://t.co/hNtStAluJH